Breakthrough technologies to treat complex oncolytic and neurological conditions

Our Technologies

New CNS Drug Delivery System by Alcyone Lifesciences Given Breakthrough Designation by FDA

Mission

At Alcyone, we are committed to developing biologically inspired and clinically relevant solutions to significantly enhance current treatment modes for patients suffering from oncolytic and chronic neurological conditions.

About Alcyone

Our Therapeutic Focus Oncology & Neuroscience

Learning Center

Our Technologies

Alcyone MEMS Cannula (AMC™)*

Alcyone technologies for chronic neuropathological conditions

Intrathecal Delivery**

Pulsar CSF Dynamic Intrathecal System by Alcyone Lifesciences

All Technologies

Upcoming Conferences & Events

Boston, MA

October 29th – 30th, 2018
TBD

*Alcyone previously sponsored the 2017 ICCS/SRHSB Joint Conference

Latest News

New CNS Drug Delivery System by Alcyone Lifesciences Given Breakthrough Designation by FDA
Alcyone Lifesciences To Present on Precision Therapy Delivery Technologies for Antisense Oligonucleotide and Gene Therapy at the 2019 Oligonucleotide Discovery and Delivery Conference
Alcyone Wins Breakthrough Device Status for Delivery Device
Alcyone Lifesciences Announces Broad Strategic Collaboration with Roche in the Field of Intrathecal Therapies
Alcyone Lifesciences Announces the Use of AMC Intratumoral Delivery Platform in the Treatment of First Patient in DNX-2440 Glioblastoma Trial
Alcyone Lifesciences Announces Research Collaboration with a Leading Biopharmaceutical Company to Improve Intrathecal Delivery of Therapies for Rare and Orphan Neurological Conditions
Alcyone Lifesciences Receives FDA Clearance for the Alivio System for the Treatment of Hydrocephalus
Alcyone Lifesciences Receives EU CE Mark Approval for Alivio Ventricular Catheter and Flusher System for Treatment of Hydrocephalus
Alcyone Lifesciences Enters into a Feasibility Study Agreement with Pfizer to Evaluate Alcyone's proprietary Pulsar™ Advanced Intrathecal Precision Delivery Platform Technology for use in Gene Therapy Targeting Central Nervous System Disorders
Lowell biotech company Alcyone announces research deal with Pfizer
Precision Intratumoral Delivery of DNX-2401 with the Alcyone MEMS Cannula
DNATrix announces successful intratumoral delivery of DNX-2401 via Alcyone's MEMS Cannula(AMC) for the targeted treatment of recurrent Glioblastoma
Lysogene and Alcyone Lifesciences Enter into a Collaboration for Mucopolysaccharidosis Type IIIA (MPS IIIA)
Dr. Olivier Danos, Cell and Gene Therapy Pioneer, Joins Alcyone Lifesciences Scientific Advisory Board

*The Alcyone MEMS Cannula (AMC™) System, a neuro-ventricular cannula, has US Food and Drug Administration (FDA) 510(k) clearance, Health Canada Licensing, and CE Marking. It is indicated for use in the U.S. and Canada for the injection of Cytarabine or the removal of cerebrospinal fluid from the ventricles of the brain during an intracranial procedure, and approved in Europe for injection or removal of substances from the brain and/or ventricles of the brain during intracranial procedures. The AMC is a dual-lumen, MR-compatible injection and aspiration cannula and can be used with existing commercial imaging and stereotactic systems. The AMC is not intended for implant, and it is intended for single patient use only.

** The Pulsar System is not yet available for commercial use and has not yet been cleared by the FDA.